Health Vidya

Linezolid for oral suspension is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus(methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae[ see Clinical Studies (14) ]. Linezolid for oral suspension is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus(methicillin-susceptible isolates only) [ see Clinical Studies (14) ]. Linezolid for oral suspension is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus(methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae. Linezolid for oral suspension has not been studied in the treatment of decubitus ulcers [ see Clinical Studies (14) ]. Linezolid for oral suspension is indicated for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus(methicillin-susceptible isolates only) or Streptococcus pyogenes[ see Clinical Studies (14) ]. Linezolid for oral suspension is indicated for the treatment of vancomycin-resistant Enterococcus faeciuminfections, including cases with concurrent bacteremia [ see Clinical Studies (14) ]. Linezolid for oral suspension is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [ see Warnings and Precautions (5.4) ]. The safety and efficacy of linezolid for oral suspension formulations given for longer than 28 days have not been evaluated in controlled clinical trials [ see Clinical Studies (14) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid for oral suspension and other antibacterial drugs, linezolid for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.